Drug intelligence / Profile preview

HSK47388

Development stage: Phase 2
Lead developer: Haisco Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

HSK47388 is an orally administered, potent, and highly selective small molecule drug developed by Haisco Pharmaceutical Group. As of mid-2025, it is in Phase 1 clinical development. Early clinical studies are designed to evaluate its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Specific details regarding its mechanism of action, molecular target, and therapeutic indication have not been disclosed in public sources, and it is being studied primarily in healthy participants rather than patients with a specific disease[1][2][5].

Targets

IL23R (Interleukin-23 Receptor)

Beyond the preview

Go deeper on HSK47388.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSK47388.

Explore the full profile